Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.
The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.
Golumbek
P T
PT
Department of Medicine, Johns Hopkins University, Baltimore, MD 21205.
Lazenby
A J
AJ
Levitsky
H I
HI
Jaffee
L M
LM
Karasuyama
H
H
Baker
M
M
Pardoll
D M
DM
D000818:Animals; D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002455:Cell Division; D002460:Cell Line; D007167:Immunotherapy; D015847:Interleukin-4 / Q000235:genetics* / Q000378:metabolism; D007680:Kidney Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008212:Lymphocyte Depletion; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D015202:Protein Engineering; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014162:Transfection
D015847:Interleukin-4